Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum-Refractory Advanced Urothelial Carcinoma.

Umang Swami,Benjamin Haaland,Adam Kessel,Roberto H. Nussenzveig,Benjamin Louis Maughan,John Esther,Deepika Sirohi,Sumanta K. Pal,Petros Grivas,Neeraj Agarwal

Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum-Refractory Advanced Urothelial Carcinoma.

2020

Umang Swami
Benjamin Haaland
Adam Kessel
Roberto H. Nussenzveig
Benjamin Louis Maughan
John Esther
Deepika Sirohi
Sumanta K. Pal
Petros Grivas
Neeraj Agarwal

Purpose:Five programmed cell death protein 1 (PD-1) or its ligand (L1) inhibitors are approved for treatment of platinum-refractory locally advanced/unresectable or metastatic urothelial carcinoma....

Keywords:

Pembrolizumab
Metastatic Urothelial Carcinoma
urothelial carcinoma
Medicine
Cancer research
Nivolumab
platinum resistance
immune checkpoint inhibitors
Atezolizumab
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations